NovaBay Pharmaceuticals Q3 2023 Gaap EPS $(0.37) Beats $(0.40) Estimate, Sales $3.27M Miss $3.55M Estimate
Author: Benzinga Newsdesk | November 09, 2023 05:30pm
NovaBay Pharmaceuticals (AMEX:
NBY) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.40) by 7.5 percent. This is a 89.43 percent increase over losses of $(3.50) per share from the same period last year. The company reported quarterly sales of $3.27 million which missed the analyst consensus estimate of $3.55 million by 8.03 percent. This is a 14.66 percent decrease over sales of $3.83 million the same period last year.
Posted In: NBY